Posts by Pradeep Natarajan, MD, MMSc
-
Lipoprotein(a), Oxidized Phospholipids Linked With CVD Severity in a Cohort Referred for Angiography
Pradeep Natarajan, MD, MMSc, Thomas C. Gilliland, MD, and colleagues demonstrated in a contemporary, statin-treated cohort that lipoprotein(a) is associated with the severity of coronary artery disease and clinical outcomes in follow-up, independently of low-density lipoprotein cholesterol levels and other established clinical predictors.
-
Rare DNA Variants Protect Against Coronary Heart Disease, Provide More Evidence for Minimizing LDL-C
By studying 19,073 participants from U.S.-based study cohorts and 190,464 UK Biobank participants, a Massachusetts General Hospital team reports rare protein-truncating variants in APOB or PCSK9 are associated with reduced low-density lipoprotein cholesterol concentrations and reduced risk of coronary heart disease.
-
BP Polygenic Risk Scores May Complement Measured BP for CVD Prevention
In a prospective cohort of 331,078 middle-aged adults, So Mi Jemma Cho, PhD, Pradeep Natarajan, MD, MMSc, and colleagues observed that genetic predisposition to hypertension informed the risk of incident cardiovascular disease, independent of measured blood pressure and antihypertensive treatment.
-
Lipoprotein(a) Prognostic of CHD in Contemporary Cohort Receiving Menopausal Hormone Therapy
Michael C. Honigberg, MD, MPP, Pradeep Natarajan, MD, MMSc, and Mark Trinder, MSc, studied 88,266 participants in the UK Biobank and found no evidence that contemporary menopausal hormone therapy reduces the lipoprotein(a)-associated risk of coronary heart disease.
-
AI Identifies Links Between Retinal Vascular Patterns and Risk of Cardiometabolic, Ocular Diseases
Measurements of retinal vascular density and branching, obtained from fundus photographs by convolutional neural networks at Massachusetts General Hospital, may be clinically useful as biomarkers of cardiometabolic disease severity and for predicting future risk of ocular diseases.
-
Clonal Hematopoiesis of Indeterminate Potential Linked to Higher Risk of Stroke
By reviewing genomic data, cardiologists at Massachusetts General Hospital confirmed that somatic age-related mutations in myeloid-lineage blood cells, termed clonal hematopoiesis of indeterminate potential, is associated with an increased risk of stroke and found the risk is highest for hemorrhagic stroke, especially subarachnoid hemorrhage.
-
Mosaic Chromosomal Alterations Increase the Risk of Diverse Infections
Pradeep Natarajan, MD, MMSc, of the Cardiovascular Research Center, and colleagues determined that mosaic chromosomal alterations (mCAs) are a risk factor for infectious disease, which is exacerbated in the setting of solid tumors. Furthermore, among COVID-19 patients, mCAs were linked to more severe disease.
-
X Chromosome Locus Is Associated with Lower Atherogenic Lipids, Favorable Cardiometabolic Traits
Variants in chromosome Xq23 are linked to reduced total cholesterol, LDL cholesterol and triglycerides, and reduced risk of coronary heart disease and type 2 diabetes, according to whole-genome data analyzed by Pradeep Natarajan, MD, MMSc, and an international team of colleagues.
-
CV Risk Associated with Premature Menopause: Clonal Hematopoiesis May Contribute
Michael C. Honigberg, MD, MPP, and Pradeep Natarajan, MD, MMSc, of the Cardiovascular Research Center at Massachusetts General Hospital, and colleagues have linked premature menopause to increased odds of age-associated mutations in blood cells, a recently recognized risk factor for cardiovascular disease.
-
Management of Blood Pressure, BMI May Reduce the Risk of Hypertensive Disorders of Pregnancy
In a large cohort of U.K. women, genetic predisposition to high blood pressure and higher body mass index was significantly associated with hypertensive disorders of pregnancy.
-
Better Guidelines Needed to Distinguish Individuals at Elevated Polygenic Risk of CAD
Current guideline-based strategies for estimating a patient's risk of coronary artery disease do not account fully for inherited susceptibility.
-
Preventing and Managing CVD in the COVID-19 Era
Experts from the Cardiovascular Disease Prevention Center at Massachusetts General Hospital share their perspective on preventing and managing cardiovascular disease during this time when routine medical care has been disrupted by the ongoing COVID-19 pandemic.
-
Both Natural and Surgical Premature Menopause Increase the Risk of Cardiovascular Disease
In a prospective cohort of 144,260 postmenopausal women, natural and surgical menopause before age 40 years were associated with a statistically significant increased risk of a composite of cardiovascular diseases.
-
Studies Uncover Cardiovascular Disease Risk Factors in Women
Researchers at Massachusetts General Hospital have found significant connections between cardiovascular disease risk and hypertensive disorders of pregnancy and early menopause.
-
Cardiovascular Risk After Hypertensive Disorder of Pregnancy Persists into Midlife
Hypertensive disorders of pregnancy are associated with a range of cardiovascular conditions later in life, including valvular disease, according to the first study that began prospective follow-up at midlife.
-
Gaps Remain in Preventative Care of Patients With Nonobstructive CAD Discovered in ED Visits
Researchers at Massachusetts General Hospital have become the first to study both hospital and long-term outpatient management after nonobstructive coronary artery disease is detected by computed tomography angiography performed in the emergency department.
-
Review: Analyzing the Latest Data on Recurrent CVD Prevention
Cardiologists at Massachusetts General Hospital review the newest evidence on how physical activity, cholesterol management, omega-3 fatty acids, hypoglycemic agents and direct-acting oral anticoagulants can aid in secondary prevention of atherosclerotic cardiovascular disease.
-
HDL Apolipoproteins May Identify Risk, Prognosis of CAD
Analysis of high-density lipoprotein (HDL) apolipoproteins, individually and together, identifies patients with coronary artery disease (CAD) and may be able to flag those at increased risk of cardiovascular death when CAD is present.
-
What Is Your New Year's Resolution?
Massachusetts General Hospital cardiologists were asked what their 2019 New Year's resolution is regarding their research and care. In this video, they give a variety of answers.
-
Deep-coverage whole genome sequences and blood lipids among 16,324 individuals
Massachusetts General Hospital investigators conducted a whole genome sequencing (WGS) screen for variants in 16,324 individuals from 4 different ancestries in order to identify genetic factors influencing blood lipid levels.
-
#AHA18: Scientific Sessions in Summary
Mass General physicians answer the question: "What was the most interesting topic presented at this year's Scientific Sessions?"
-
New Cholesterol Treatment Guidelines: A Mass General Perspective
Pradeep Natarajan, MD, MMSc, weighs in on the American College of Cardiology and the American Heart Association's updated guidelines on cholesterol management.
-
#AHA18 on Twitter: New Cholesterol Guidelines, the PIONEER-HF Trial and More
Health care professionals at this year’s American Heart Association's Scientific Sessions discussed late-breaking research, innovative treatment approaches and brand new guidelines. The conversations carried over from the podium and conference halls onto Twitter.
-
Five Sessions to See at #AHA18
From machine learning to metabolic disease, the topics discussed and presented by Mass General clinicians and researchers at #2018 foster a dialogue that contributes to the transformation of cardiovascular care in the practice setting and the improvement of heart health for patients.
-
Using Polygenic Scores to Identify Risk of Afib and 4 Other Common Diseases
Polygenic risk scores developed at Massachusetts General Hospital are equivalent to or better than rare monogenic mutations in identifying a specific individual’s risk of certain common diseases, including coronary artery disease, atrial fibrillation and type 2 diabetes.
-
Expanding the Primary Prevention Role of Lifestyle and Statins to Reduce First Cardiac Event Risk
Two recent high-profile studies from Massachusetts General Hospital’s Preventive Cardiology group expand practitioners’ toolkit during a consult by providing patients with two action steps to help manage risk of premature death from heart disease.
-
Gene Knockout Testing Evidences APOC3 as a Target for Therapeutics
pLoF mutations that cause gene knockouts among those with high rates of consanguinity evidence APOC3 and other cardiovascular markers as therapy targets.
-
‘Human Knockout Project’ in a Pakistani Population with High Levels of Consanguinity
Experimental “knockout” models are useful to study gene function. This poster highlights naturally-occurring null mutations and their phenotypic consequences in humans.
Biography
Dr. Natarajan is the Director of Preventive Cardiology at Massachusetts General Hospital. He received his BA in molecular biology with Honors and Phi Beta Kappa in 2004 from the University of California, Berkeley. He received his MD with Alpha Omega Alpha in 2008 from the University of California, San Francisco. He received his MMSc in biomedical informatics in 2015 from Harvard Medical School. Dr. Natarajan completed his internship and residency in internal medicine at the Brigham and Women's Hospital, Harvard Medical School in 2011. He completed his clinical and research fellowship in cardiovascular medicine at the Massachusetts General Hospital, Harvard Medical School in 2015. In 2012, he was awarded the national American Heart Association's Laennec Young Clinician Award.
Dr. Natarajan researches the genetic drivers of human atherosclerosis using genetic epidemiology, large-scale sequencing studies, and genotype-driven human investigation under the mentorship of Dr. Sekar Kathiresan and Dr. Christopher O'Donnell. In addition to his research efforts, Dr. Natarajan is a clinical cardiologist focusing on heart attack prevention, cardiovascular risk reduction, premature heart attack, lipid disorders, and cardiovascular genetics based at the MGH Cardiovascular Disease Prevention Center.
Cardiovascular Care at Mass General
At Mass General, our world-class physicians and nurses specialize in specific forms of both heart and vascular disease, and work closely together to offer leading treatments and preventive care for cardiovascular conditions.